HighLife
Paris
About HighLife
HighLife is a company focused on Transcatheter Mitral Valve Replacement (TMVR). The technology is intended for treatment of patients suffering from mitral valve regurgitation and is currently in a stage of clinical evaluation. The company was co-founded in 2010 by Mr. Georg Börtlein, President & CEO. The intent is to provide a minimally invasive prosthetic mitral valve that is implanted on a beating heart, while preserving the native valve structure and respecting the surrounding anatomy. Ease and safety of use and delivery are key elements of the HighLife technology.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $10K – $50K
- Total funding: $50.3M
- Funding stage: Late Stage Venture
- Last round: Series C (Dec 2020)
- Website: highlifemedical.com
Industries & Categories
Health Care, Medical, Medical Device
Social Profiles
Canonical: https://fsome.com/organization/highlife-99114 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.